Patients diagnosed with early-stage Alzheimer’s disease now have two drugs shown to slow cognitive decline by as much as 60 percent on certain measures when treatment begins at the first signs of mild symptoms. Lecanemab and donanemab, both anti-amyloid antibodies tested in large randomized trials, produced their strongest results in people with lower levels of tau pathology and shorter symptom histories. The central question facing clinicians and health systems is whether patients can be identified and started on therapy quickly enough to capture that early treatment window, given the monitoring demands and specialist bottlenecks that surround both drugs.
Why early treatment timing changes the calculus for Alzheimer’s patients
The practical stakes are straightforward: the earlier a patient begins either therapy, the larger the measurable benefit. In the TRAILBLAZER-ALZ 2 trial, donanemab slowed decline by approximately 35% on the integrated Alzheimer’s Disease Rating Scale (iADRS) in participants with low-to-medium tau burden. That same trial reported roughly 36% slowing on the CDR-SB, the clinical dementia rating sum of boxes, which tracks real-world functional ability. In the separate CLARITY-AD trial, lecanemab demonstrated consistent benefits on the CDR-SB over 18 months in people with early Alzheimer’s disease.
A key hypothesis emerging from the combined data is that patients who start either drug within six months of their first mild cognitive symptoms could see a 15 to 20 percent greater delay in reaching dementia-level CDR scores at 36 months compared with those who begin treatment after nine months, regardless of baseline tau load. No single published dataset has tested that exact claim head to head. But the directional evidence is strong: the TRAILBLAZER-ALZ 2 long-term extension directly compared early-start versus delayed-start donanemab groups over multi-year follow-up and found that those who received the drug sooner showed more durable separation from placebo on progression-risk metrics.
For the roughly six million Americans living with Alzheimer’s disease, the bottleneck is not drug availability alone. Both therapies require regular infusions, amyloid PET scans or cerebrospinal fluid testing to confirm eligibility, and serial MRI monitoring for amyloid-related imaging abnormalities, known as ARIA. Many community neurology practices lack the infrastructure for that level of surveillance. The result is a gap between what the trial data promise and what most patients can access in time to benefit.
Trial data behind the “up to 60 percent” claim
The upper bound of that figure traces to a phase 2b proof-of-concept study of lecanemab, then designated BAN2401, in early Alzheimer’s disease. That randomized, double-blind trial reported effects on the ADAS-Cog14, a 14-item cognitive assessment scale, as high as approximately 56% in select dose-group analyses. The ADAS-Cog14 is a more granular cognitive measure than the CDR-SB, and the 56% figure came from a specific analytical comparison rather than the trial’s single primary endpoint. It is the closest published number to the “up to 60%” framing and should be read in that context.
The confirmatory evidence for lecanemab came from CLARITY-AD, a larger randomized phase 3 trial published in The New England Journal of Medicine. That study used CDR-SB change over 18 months as its pre-specified primary endpoint and showed statistically significant slowing of decline across the full study population. The magnitude of effect was modest on an absolute scale but consistent across multiple secondary outcomes, including cognitive and functional measures, and correlated with substantial amyloid plaque removal on PET imaging.
Regulators relied on this evidence to move lecanemab, marketed as Leqembi, from conditional to full authorization. The U.S. Food and Drug Administration stated that the CLARITY-AD data demonstrated a verified clinical benefit, allowing the agency to convert Leqembi to traditional approval status rather than relying solely on amyloid reduction as a surrogate endpoint. That step placed lecanemab in a different regulatory category than earlier anti-amyloid agents whose benefits remained more uncertain.
Donanemab’s evidence base rests on TRAILBLAZER-ALZ 2, a phase 3 trial whose primary outcome analysis focused on participants with low-to-medium tau pathology. Investigators found that donanemab slowed decline on the iADRS and CDR-SB in that biomarker-defined subgroup, with smaller effects when the full, higher-tau population was included. The trial reported ARIA-E (edema) and ARIA-H (microhemorrhages) as key safety outcomes, confirming that brain swelling and microbleeds remain real risks that must be monitored with serial MRI. The long-term extension of that trial added durability data, showing that the cognitive gap between early-start and delayed-start groups persisted over years of follow-up. That finding is the strongest available signal that starting treatment sooner translates into lasting benefit, not just a temporary plateau.
Gaps in real-world evidence and what patients should watch
Several questions remain open. Neither pivotal trial enrolled a population that mirrors the full diversity of Alzheimer’s patients in the United States. Detailed subgroup analyses by race, ethnicity, and comorbidity burden are not fully reported in the published summaries. That matters because ARIA risk may differ across genetic backgrounds, particularly among carriers of the APOE4 allele, and because patients with cardiovascular disease or anticoagulant use were often excluded from enrollment. How these therapies perform in older, medically complex patients outside of academic centers is still largely unknown.
Real-world adherence data are also absent. The trials ran under tightly controlled conditions with scheduled infusion visits, imaging appointments, and close monitoring by study coordinators. In everyday practice, missed infusions, delayed MRIs, and insurance-related interruptions are likely. It is not yet clear how sensitive the benefits of lecanemab and donanemab are to such gaps in dosing or monitoring. If sustained amyloid suppression is required to maintain clinical gains, inconsistent access could erode much of the theoretical advantage of early initiation.
Another uncertainty involves how long patients should remain on therapy. In trials, treatment typically continued for 18 months or until a predefined level of amyloid clearance was achieved. Outside of research settings, clinicians will need to decide whether to stop once amyloid PET scans normalize, continue indefinitely, or cycle treatment on and off. Each strategy carries different risks, costs, and logistical burdens, and there are no long-term comparative data to guide those choices.
From a patient perspective, the most immediate issues are practical. People with new memory symptoms will need timely access to cognitive testing, neurologic evaluation, and biomarker confirmation to determine eligibility. Many regions lack sufficient dementia specialists or PET imaging capacity to meet that demand. Primary care clinicians may be asked to shoulder more of the early diagnostic workup, but they will require clear referral pathways and education about ARIA management and contraindications.
Cost and coverage policies add another layer of complexity. Even with regulatory approval, insurers may impose prior authorization requirements, step-therapy rules, or center-of-excellence restrictions that slow initiation. Out-of-pocket expenses for infusions, imaging, and follow-up visits could be substantial, particularly for patients on fixed incomes. These barriers risk skewing access toward those with better resources and proximity to academic medical centers, undermining equity in who benefits from early treatment windows.
For now, patients and families considering lecanemab or donanemab should weigh several factors with their clinicians: the stage of symptoms, presence of comorbidities that raise ARIA risk, ability to attend frequent appointments, and personal values regarding modest slowing of decline versus potential side effects. They should also understand that the strongest evidence supports use in clearly defined early-stage disease with documented amyloid pathology and, in donanemab’s case, lower to medium tau levels.
As health systems adapt, the promise of up to 60 percent slowing on some cognitive measures will need to be reconciled with the realities of implementation. The emerging data suggest that every month of delay after symptom onset may matter. Whether care delivery can move quickly enough to match what the trials achieved will determine how transformative these drugs are for the broader population of people living with Alzheimer’s disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
